Tuberculin

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Belgium: Tuberculin PPD; Bulgaria: PPD Tuberculin Mammalian; Czech Republic: Tuberculin PPD; Denmark: Tuberkulin PPD; Estonia: Tuberculin PPD; Finland: Tuberculin PPD; France: Tubertest; Germany: Tuberkulin PPD; Ireland: Tuberculin PPD; Netherlands: Tuberculine PPD; Portugal: Tuberculina PPD; Romania: Antigene Pentru IDR (Tuberculina); Spain: Tuberculina PPD, Tubersol; Sweden: Tuberculin PPD; UK: Tuberculin PPD.

North America

USA: Aplisol, Tubersol.

Latin America

Argentina: Tuberculina PPD.

Drug combinations

Chemistry

Pharmacologic Category

Diagnostic Agents; Tuberculosis. (ATC-Code: V04CF01).

Mechanism of action

Tuberculosis results in individuals becoming sensitized to certain antigenic components of M. tuberculosis organism. Culture extracts called tuberculins are contained in tuberculin skin test preparations. Upon intracutaneous injection of these culture extracts, a classic delayed (cellular) hypersensitivity reaction occurs. This reaction is characteristic of a delayed course (peak occurs >24 hours after injection, induration of skin secondary to cell infiltration, and occasional vesiculation and necrosis). Delayed hypersensitivity reactions to tuberculin may indicate infection with a variety of nontuberculosis mycobacteria, or vaccination with live attenuated mycobacterial strain of M. bovis vaccine, BCG, in addition to previous natural infection with M. tuberculosis.

Therapeutic use

Skin test in diagnosis of tuberculosis.

Pregnancy and lactiation implications

Pregnancy not a contraindication to testing.

Unlabeled use

Contraindications

Hypersensitivity to tuberculin purified protein derivative (PPD) or any component of the formulation. Previous severe reaction to tuberculin PPD skin test (TST).

Warnings and precautions

Do not administer to persons with extensive burns or with eczema. Do not administer to persons with documented tuberculosis or clear history of treatment for tuberculosis. Skin testing may be deferred with major viral infections. Very young children (<6 weeks of age) may also have absent or delayed response. For intradermal administration only; do not administer I.V., I.M., or SubQ. Possible allergic reactions. Patients with previous severe reaction to TST (vesiculation, ulceration, necrosis) at injection site should not receive tuberculin PPD again. Tuberculous or other bacterial infections, viral infection, live virus vaccination, malignancy, immunosuppressive agents, and conditions which impair immune response may cause decreased response to test. Skin testing may be deferred with live-virus vaccination within 1 month.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart